Tivic Health Q2 2024 revenue $140K, net loss $1.3M; Phase 1 VNS results, cost cuts

Valion Bio, Inc.

2024-Q2 EPS reported -$1.00 vs consensus -$6.12 ▲ beat (+83.7%)

Q2 2024 revenue $140K vs $203K in Q2 2023; H1 2024 revenue $474K, down 12% YoY.
Net loss Q2 2024 $1.3M vs $2.1M; H1 net loss $2.7M, $1.5M improvement from H1 2023.
Gross margin improved to 42% in H1 2024 from 32% in H1 2023 due to cost reductions.
Cash and equivalents $3.7M as of June 30, 2024; raised $3.3M net from May 2024 offering.
Phase 1 VNS trial results with Feinstein Institutes; ClearUP 2.0 launched; lease and logistics savings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.